Meta-analysis

Lee, Hyun Ki; Eom, Chun Sick; Kwon, Young Min; Ahn, Jongmin; Kim, Sarah; Park, Sang Min

doi:10.1097/meg.0b013e328355e289

Cited by 14 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, we identified 4471 studies, scrutinized 252 full-text articles, and ultimately included 45 meta-analyses (17.9%) in this umbrella review (Figure 1), corresponding to 695 studies, 1012 study estimates, and 13 putative risks (Figure 2). The 207 excluded articles (82.1%) and the reasons for their exclusion are provided in eTable 1 in the Supplement.…”

Section: Resultsmentioning

confidence: 99%

Association of Antidepressant Use With Adverse Health Outcomes

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Association of Antidepressant Use With Adverse Health Outcomes

et al. 2019

View full text Add to dashboard Cite

show abstract

“…SERT targeted drugs have anti-tumor activities [ 33 ], however, their underlying mechanisms have not been established. SSRIs exert anti-cancer effects in a variety of ways.…”

Section: Discussionmentioning

confidence: 99%

Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment

Xiao

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background Serotonin signaling has been associated with tumorigenesis and tumor progression. Targeting the serotonin transporter to block serotonin cellular uptake confers antineoplastic effects in various tumors, including colon cancer. However, the antineoplastic mechanism of serotonin transporter inhibition and serotonin metabolism alterations in the absence of serotonin transporter have not been elucidated, especially in colon cancer, which might limit anti-tumor effects associating with targeting serotonin transporter. Methods The promotion in the uptake and catabolism of extracellular tryptophan and targeting serotonin transporter was detected by using quantitative reverse-transcription polymerase chain reaction, western blotting and liquid chromatography tandem mass spectrometry. Western blotting Immunoprecipitation and immunofluorescence was utilized to research the serotonylation of mTOR by serotonin and serotonin transporter inhibition. The primary mouse model, homograft model and tissue microarry was used to explore the tryptophan pathway in colon cancer. The cell viability assay, western blotting, xenograft and primary colon cancer mouse model were used to identify whether the combination of sertraline and tryptophan restriction had a synergistic effect. Results Targeting serotonin transporter through genetic ablation or pharmacological inhibition in vitro and in vivo induced a compensatory effect by promoting the uptake and catabolism of extracellular tryptophan in colon cancer. Mechanistically, targeting serotonin transporter suppressed mTOR serotonylation, leading to mTOR inactivation and increased tryptophan uptake. In turn, this process promoted serotonin biosynthesis and oncogenic metabolite kynurenine production through enhanced tryptophan catabolism. Tryptophan deprivation, or blocking its uptake by using trametinib, a MEK inhibitor, can sensitize colon cancer to selective serotonin reuptake inhibitors. Conclusions The present study elucidated a novel feedback mechanism involved in the regulation of serotonin homeostasis and suggested innovative strategies for selective serotonin reuptake inhibitors-based treatment of colon cancer.

show abstract

“…In patients, FLX treatment was reported to reduce the risk of colon cancer to almost 50% [60] . Chubak et al [61] also observed that FLX reduced the risk of colon cancer in humans, while one meta-analysis study suggested that FLX does not act on colon cancer [62] . Studies with animal models support the idea of FLX reducing colon cancer incidence in different animal models, such as carcinogen induced preneoplastic lesions and tumors in rats and mice, and xenograft tumors in immunosuppressed rats [38,[63][64][65] .…”

Section: Flx Takes Energy Generation Un-der Control To Reduce Malignamentioning

confidence: 98%

Antidepressant fluoxetine and its potential against colon tumors

Stopper

Garcia

Waaga-Gasser

et al. 2014

WJGO

View full text Add to dashboard Cite

Colon cancer is one of the most common tumors worldwide, with increasing incidence in developing countries. Patients treated with fluoxetine (FLX) have a reduced incidence of colon cancer, although there still remains great controversy about the nature of its effects. Here we explore the latest achievements related to FLX treatment and colon cancer. Moreover, we discuss new ideas about the mechanisms of the effects of FLX treatment in colon cancer. This leads to the hypothesis of FLX arresting colon tumor cells at the at G1 cell-cycle phase through a control of the tumor-related energy generation machinery. We believe that the potential of FLX to act against tumor metabolism warrants further investigation. © 2014 Baishideng Publishing Group Co., Limited. All rights reserved. Key words: Fluoxetine; Colon cancer; Cancer therapy; Tumor metabolismCore tip: It is currently thought that aerobic glycolysis is key for understanding cell survival in the hostile tumor microenvironment. Then, the antidepressant fluoxetine (FLX) has been shown to reduce colon tumor growth in animals and colon cancer incidence in humans. Here, we explore new perspectives of FLX reducing the development of colon tumors through a blockage in tumor metabolism. This perspective review is based on our current unpublished experimental dataset which shows FLX as a potential co-chemotherapeutic agent for colon cancer therapy.Stopper H, Garcia SB, Waaga-Gasser AM, Kannen V. Antidepressant fluoxetine and its potential against colon tumors.

show abstract

Meta-analysis

Abstract: Our research shows that the use of SSRIs does not increase the risk of colorectal cancer. Further studies are needed to confirm the association between SSRIs and colorectal cancer.

Cited by 14 publications

References 22 publications

Association of Antidepressant Use With Adverse Health Outcomes

Association of Antidepressant Use With Adverse Health Outcomes

Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment

Antidepressant fluoxetine and its potential against colon tumors

Contact Info

Product

Resources

About